Netcapital Inc.’s Portfolio Company Vymedic to Deliver Clinically Proven Antiviral to Market in Time for Flu Season

BOSTON--(BUSINESS WIRE)-- Netcapital Inc. (OTC: VSTRD) announced that portfolio company Vymedic’s clinically proven antiviral will be delivered to market this December, in time for flu season. Vymedic has partnered with a premier nutraceutical manufacturer to produce Vymune®, the company’s innovative, patented approach to helping millions impacted by influenza, the common cold and other viruses. Vymune’s® all natural, amino acid-based formula will be available in rapid melt away tablets, sold over the counter via Amazon.com. Vymedic is currently engaged in a round of equity fundraising via Netcapital.

“Developing Vymune® has been a passion project for our entire team. After years of research, development and testing, it is truly gratifying to be able to bring Vymune® to market,” said Cynthia Winning, Founder and CEO of Vymedic. “Netcapital Advisors’ deep expertise, investor experience and commitment to our mission have been critical to the success of our ongoing capital raise and have helped bring our initial product launch to fruition.”

“We look forward to continuing to work collaboratively with Netcapital Advisors to help millions with an unmet need and accelerate the realization of our vision for Vymedic,” Ms. Winning added.

“Vymedic’s innovative formula has the potential to help millions who suffer from viral infections like the flu; it’s an important and timely cause,” commented Cecilia Lenk, Netcapital Inc.’s CEO. “We are thrilled to help Vymedic deliver Vymune® to consumers and achieve this significant milestone. We look forward to continuing our work together and leveraging our experience and resources to advance Vymedic's mission."

About Vymedic:

Vymedic’s patented immune supplement, Vymune®, has been scientifically proven to suppress influenza, the common cold and similar viruses. The product has also been shown to be safer and more effective than competing antiviral drugs or supplements. Vymune also delivers superior immune support to protect and defend health. Vymune’s® all natural, amino acid-based formula will be available in rapid melt away tablets, sold via Amazon.com.

The creation of Vymune® leverages years of research and development that led to transformative breakthroughs in amino acids and metabolism; Vymedic holds over twenty patents. To prove Vymune’s® safety and efficacy, Vymedic has conducted ten years of research– including a randomized, double-blind, placebo-controlled, human clinical trial - and pre-clinical in vitro and in vivo studies partnering with national, university, and government laboratories. Please visit https://vymedic.com to learn more.

About Netcapital Inc.:

Netcapital Inc. is a publicly traded fintech company dedicated to democratizing private capital markets and empowering entrepreneurs to succeed. We help companies at all stages to build, grow and fund their businesses with a full range of services from strategic advice to raising capital. Netcapital.com’s online private investment platform employs powerful and scalable technology that connects entrepreneurs and investors, enabling companies to raise capital digitally. Netcapital.com provides investor access to pre-IPO investment opportunities as well as potential liquidity in privately held shares via a Secondary Transfer Platform. Through Netcapital Advisors, our team of professional investors and digital marketing experts offers deep expertise across a range of verticals including biotech, technology and public policy. We also take equity stakes in select companies with disruptive technologies. To learn more about how Netcapital Inc. can help your business please visit our website at https://NetcapitalInc.com.

The Netcapital funding portal is registered with the U.S. Securities & Exchange Commission (SEC) and is a member of the Financial Industry Regulatory Authority (FINRA), a registered national securities association. For more information, please visit https://netcapital.com.

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Contacts

NETCAPITAL INC.:
Coreen Kraysler, CFA
CFO
781-925-1700
coreen.kraysler@netcapital.com

Callie Gauzer, MSIM, CAIA
Director, Investor Relations
781-925-1700
callie.gauzer@netcapital.com

 
 

Source: Netcapital Inc.

Back to news